Imunon, Inc.
IMNNImunon, Inc. is a clinical-stage biotechnology company focused on developing advanced immunotherapies and next-generation DNA vaccines to treat cancer and infectious diseases.
Table of contents
Earnings
Next report
Aug 4, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Imunon, Inc. is a clinical-stage biotechnology company focused on developing advanced immunotherapies and next-generation DNA vaccines to treat cancer and infectious diseases. The company leverages its proprietary TheraPlas and PlaCCine technology platforms to induce the body's own immune system to produce therapeutic proteins and generate immune responses. Its primary value proposition lies in creating targeted treatments for difficult-to-treat malignancies, such as advanced ovarian cancer, through gene-based delivery systems.
A clinical-stage developer with Fast Track and Orphan Drug designations for its lead candidate, competing against major pharmaceutical firms in the oncology and vaccine space.
Questions, answered.
- What is Imunon, Inc.'s market cap?
- Imunon, Inc. (IMNN) has a market capitalization of $8.4M and trades on NASDAQ.
- Who are Imunon, Inc.'s competitors?
- Imunon, Inc.'s key competitors include Inovio Pharmaceuticals, Sanofi, Merck, and others. These companies compete in similar markets and product categories.
- Who does Imunon, Inc. partner with?
- Imunon, Inc.'s notable partners include National Institutes of Health, Break Through Cancer Foundation.
- Where is Imunon, Inc. headquartered?
- Imunon, Inc. is headquartered in United States of America and employs approximately 33 people. It has been publicly traded since 1995.